Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat for GVHD Prevention
NCT02588339Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in graft-versus-host disease (GVHD), sponsored by Moffitt Cancer Center. Primary endpoint: Number of Participants Stratified by Acute Graft Versus Host Disease GVHD Stage at 100 days. Started Mar 2016; status: completed.
02
Drugs
panobinostat
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02588339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02588339.